J&J Raises 2026 Outlook After Q2 Beat, Eyes First $100B Revenue Year
JNJ sits 64% above its 52-week low of $154.8.
Summary
Johnson & Johnson lifted its full-year 2026 guidance following a strong Q2, now projecting reported sales of $100.8B–$101.4B and adjusted EPS of $11.60–$11.75. The raise comes after Q2 sales of $25.31B and adjusted EPS of $2.90 topped consensus, driven by 7.8% growth in Innovative Medicine. CEO Joaquin Duato said the company is on track to surpass $100B in annual revenue for the first time in its 140-year history. Despite the beat and raised outlook, shares dipped 0.6% to $252.32, suggesting the market may have priced in the strength or is weighing ongoing Stelara biosimilar headwinds. The guidance raise signals confidence in new product momentum, but the muted stock reaction warrants attention.
At the time of this announcement, JNJ was trading at $253.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $610.2B. The 52-week trading range was $154.80 to $269.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: ShareCast.